Trials / Completed
CompletedNCT00480194
Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Nycomed · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | xylometazoline hydrochloride and ipratropium bromide (ZyComb) | Common cold in a real-life OTC setting |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2007-05-30
- Last updated
- 2012-05-07
Source: ClinicalTrials.gov record NCT00480194. Inclusion in this directory is not an endorsement.